Skip to Primary Navigation

Skip to main content

FDA issues warnings to 30 telehealth companies over marketing violations

A photo of a Mounjaro GLP-1 weight loss drug pen and a bathroom floor scale.
Photo: Peter Dazeley/Getty Images
Kevin Kinsella profile image

Kevin Kinsella

2 min read

The letters warning of false or misleading marketing claims point to a transition from the agency’s traditional complaint-driven oversight to a more proactive monitoring system.

The US Food and Drug Administration (FDA) has issued 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites. 

Sent on February 20 and made public in early March, the letters cite violations including claims implying compounded products are the same

The

, , , , , , , ,

Get full access, free for a month

Start your 28-day free trial to continue reading and access
all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience